Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know

Journal of the American Academy of Dermatology

Volumn 66, Issue 2, 2012, Pages 317-322

  Strober, Bruce E ^a   Armour, Katherine ^b   Romiti, Ricardo ^c   Smith, Catherine ^d   Tebbey, Paul W ^e   Menter, Alan ^f   Leonardi, Craig ^g  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b SKIN AND CANCER FOUNDATION   (Australia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e International Psoriasis Council   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bioequivalence; biologics; biopharmaceuticals; biosimilars; follow on biologics; generics; pharmacokinetics; psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETA1A INTERFERON; BIOSIMILAR AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GAMMA INTERFERON; GENERIC DRUG; HYDROCORTISONE; INFLIXIMAB; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

ANEMIA; ANKYLOSING SPONDYLITIS; CENTRIFUGATION; CHROMATOGRAPHY; CROHN DISEASE; DERMATOLOGIST; DERMATOLOGY; DISEASE SEVERITY; DRUG COST; ELUTION; FILTRATION; HUMAN; IMMUNOGENICITY; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT CARE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PURE RED CELL ANEMIA; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 84862935674     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.08.034     Document Type: Editorial

References (28)

1. M.A. Hassali, A.A. Shafie, S. Jamshed, M.I. Ibrahim, and A. Awaisu Consumers' views on generic medicines: a review of the literature Int J Pharm Pract 17 2009 79 88
2. US Food and Drug Administration. FDA listing of authorized generics. Available from: URL: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ UCM183605.pdf. Accessed October 3, 2010.
3. J.R. Peters, D.R. Hixon, D.P. Conner, B.M. Davit, D.M. Catterson, and C.M. Parise Generic drugs-safe, effective, and affordable Dermatol Ther 22 2009 229 240
4. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
5. D.M. Dudzinski, and A.S. Kesselheim Scientific and legal viability of follow-on protein drugs N Engl J Med 358 2008 843 849
6. Sigma-Aldrich Co. LLC. Sigma Aldrich Product Directory Home. Available from: URL: http://www.sigmaaldrich.com. Accessed January 16, 2011.
7. Enbrel (etanercept) [package insert] 2010 Immunex Corp Thousand Oaks, CA
8. Humira (adalimumab) [package insert] 2010 Abbott Laboratories North Chicago, IL
9. R. Savan, S. Ravichandran, J.R. Collins, M. Sakai, and H.A. Young Structural conservation of interferon gamma among vertebrates Cytokine Growth Factor Rev 20 2009 115 124
10. D.E. Furst, R. Wallis, M. Broder, and D.O. Beenhouwer Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Semin Arthritis Rheum 36 2006 159 167 (Pubitemid 44691882)
11. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 2002 457 462 (Pubitemid 37361488)
12. H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann Oncol 19 2008 411 419 (Pubitemid 351325660)
13. D. Goldsmith, M. Kuhlmann, and A. Covic Through the looking glass: the protein science of biosimilars Clin Exp Nephrol 11 2007 191 195 (Pubitemid 47476796)
14. R. Fleischmann, and D. Shealy Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis Mol Interv 3 2003 310 318
15. A. Rubbert-Roth, and A. Finckh Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review Arthritis Res Ther 11 Suppl 2009 S1
16. J. Woodcock, J. Griffin, R. Behrman, B. Cherney, T. Crescenzi, and B. Fraser The FDA's assessment of follow-on protein products: a historical perspective Nat Rev Drug Discov 6 2007 437 442 (Pubitemid 47078655)
17. Efalizumab: anti-CD11a monoclonal antibody-Genentech/Xoma, HU 1124, hu1124, xanelim Drugs R D 3 2002 40 43
18. Office of Science and Technology Policy. Coordinated framework for regulation of biotechnology. Available from: URL: http://usbiotechreg.nbii.gov/ coordinated-framework-1986-Federal-register.html. Accessed October 3, 2010.
19. D. Gingery FDA looks to middle ground at biologics hearing Skin Allergy News 41 2010 38
20. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005) 2006 EMEA London
21. European Medicines Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMEA/CHMP/BWP/49348/2005) 2006 EMEA London
22. Australian Government-Department of Health and Ageing. Discussion paper on similar biological medicinal products (SBMPs); July 10, 2010. Available from: URL: http://pbs.au.gov. Accessed February 9, 2011.
23. National Health Surveillance Agency (ANVISA RDC) resolution 55/2010. Brazilian Official Gazette. December 17, 2010.
24. G.M. Hackbarth, F.J. Crosson, and M.E. Miller Report to the Congress: improving incentives in the Medicare program 2009 Medicare Payment Advisory Commission Washington (DC)
25. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
26. E.M. Jahn, and C.K. Schneider How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations N Biotechnol 25 2009 280 286
27. H. Li d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins Curr Opin Biotechnol 20 2009 678 684
28. A.B. Kimball, D. Pariser, P.S. Yamauchi, A. Menter, C.F. Teller, and Y. Shi OBSERVE-5, an observational post-marketing safety surveillance registry of etanercept for the treatment of psoriasis: a simple model for studying new psoriasis therapies Psoriasis Forum 16 2010 3 7